Actively Recruiting
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Led by Caribou Biosciences, Inc. · Updated on 2025-09-25
50
Participants Needed
16
Research Sites
251 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
CONDITIONS
Official Title
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with relapsed or refractory multiple myeloma with measurable disease
- Have received at least three prior treatments for multiple myeloma including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody
- Have an Eastern Cooperative Oncology Group performance status of 0 or 1
- Have adequate blood, kidney, liver, lung, and heart function
You will not qualify if you...
- Have received prior CAR-T cell therapy targeting any antigen
- Had an autologous stem cell transplant within 6 weeks before lymphodepletion
- Had an allogeneic stem cell transplant within 6 months before lymphodepletion
- Have known active or prior central nervous system involvement
- Had a stroke or seizure within 6 months before consent
- Are seropositive for or have a history of HIV infection
- Received a live attenuated vaccine within 4 weeks before lymphodepletion
- Have hepatitis B or hepatitis C infection
- Have known life-threatening allergies or intolerance to CB-011 or its ingredients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 16 locations
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Actively Recruiting
2
CU Anschutz Medical Campus, Anshutz Cancer Pavillion
Aurora, Colorado, United States, 80045
Actively Recruiting
3
Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics
Miami, Florida, United States, 33136
Actively Recruiting
4
University of Kentucky/ Markey Cancer Center
Lexington, Kentucky, United States, 40536
Actively Recruiting
5
Hackensack Meridian John Theurer Cancer Center
Hackensack, New Jersey, United States, 07601
Actively Recruiting
6
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Actively Recruiting
7
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
8
Levine Cancer Institute
Charlotte, North Carolina, United States, 28204
Actively Recruiting
9
Duke University Health System (DUHS)
Durham, North Carolina, United States, 27705
Actively Recruiting
10
Oncology Hematology Care, Inc
Cincinnati, Ohio, United States, 45236
Actively Recruiting
11
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Actively Recruiting
12
Tennessee Oncology
Nashville, Tennessee, United States, 37203
Actively Recruiting
13
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390
Actively Recruiting
14
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States, 84112
Actively Recruiting
15
Virginia Commonwealth University
Richmond, Virginia, United States, 23235
Actively Recruiting
16
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
Research Team
C
Caribou Biosciences
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here